Lilly sets date for move from Faris campus downtown
Work force reductions, new business structure make leased office space unnecessary. Moves will begin in late June.
Eli Lilly and Co.
Articles
Lilly diabetes drug may have cancer risk, FDA says
Once-weekly form of Byetta is awaiting the FDA’s OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
Louisiana gets $20M in Lilly drug settlement
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
Lilly wins court ban on generic copy of Gemzar
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
Lilly drug wins U.K. backing as cancer therapy
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
Eli Lilly spent $2.2 M lobbying in 4th quarter
Lilly’s lobbying spending represents a 36-percent drop from the final quarter of 2008, even though the Congressional debate
over health care reform peaked during the last quarter of 2009.
Lilly to let 115 workers go in new outsourcing deal
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Lilly eyes more animal-health acquisitions
Eli Lilly is interested in assets that may be offered for sale as a result of Sanofi-Aventis SA and Merck & Co.’s plan to
combine their veterinary units.
Lilly sues Hospira over generic version of Gemzar
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the
cancer drug Gemzar before a patent on the medicine expires in 2013.
Lilly Endowment’s assets drop more than foundation peers
Once the nation’s wealthiest foundation, Indianapolis-based Lilly Endowment now ranks ninth among its grant-making
peers. The endowment’s value fell 15 percent last year, to an estimated $4.8 billion.
Bill kicks off years of change for local health care players
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Lilly sues to block generic of Adcirca lung treatment
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
Lilly victim of theft from Connecticut warehouse
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Lilly buys right to underarm lotion for low sex drive
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Lilly pays $50M-plus for rights to testosterone lotion
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
FDA says ‘not yet’ on Lilly’s once-weekly Byetta
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
Eli Lilly to buy European rights to Pfizer animal products
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Three Indiana companies among world’s most admired
Brightpoint, WellPoint and Cummins are recognized by Fortune magazine as being among the best in their industries.
Market surge doesn’t lift Lilly Endowment
Lilly Endowment’s resistance to diversify its holdings reached a new height last year, as it failed to sell a single share
of the underperforming Eli Lilly and Co. stock while the broader market surged.
Cornelius to retire as Bristol-Myers Squibb CEO
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.